A randomized Phase I/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants

• Príomhchruthaitheoirí: Vibhu Kanchan (Údar), Khalequ Zaman (Údar), Asma Binte Aziz (Údar), Sheikh Farzana Zaman (Údar), Farzana Zaman (Údar), Warda Haque (Údar), Mahbuba Khanam (Údar), Mohammad Mahbubul Karim (Údar), Sachin Kale (Údar), Syed Khalid Ali (Údar), Michelle G. Goveia (Údar), Susan S. Kaplan (Údar), Davinder Gill (Údar), Wasif Ali Khan (Údar), Mohammad Yunus (Údar), Ajitpal Singh (Údar), John D. Clemens (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Taylor & Francis Group, 2020-03-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Objectives: To assess the safety and reactogenicity of single oral dose of heat-stable rotavirus vaccine (HSRV) in healthy adults aged 18-45 years followed by assessment of safety, reactogenicity, and immunogenicity of three doses of HSRV in healthy infants aged 6-8 weeks at enrollment. Trial Design...